Innovative Diagnostic Solutions Sanguina has developed proprietary at-home testing and non-invasive diagnostic tools focused on anemia detection, such as the AnemoCheck app and Fingernail Selfie technology. This positions the company as a leader in accessible health monitoring, presenting opportunities to partner with healthcare providers and insurance companies interested in expanding at-home diagnostics.

Strong Funding and Recognition With recent Series A financing of 2.8 million dollars and recognition as a grand prize winner in the Rapid Acceleration of Diagnostics challenge, Sanguina demonstrates strong investor confidence and industry validation. These credentials can aid in attracting strategic partners or clients looking for innovative health technology solutions.

Regulatory Milestones The recent FDA clearance for the AnemoCheck Home indicates the company's successful navigation of regulatory pathways, making their products appealing for health systems and direct-to-consumer markets seeking compliant and reliable diagnostic tools.

Market Expansion Potential Sanguina’s focus on consumer-friendly apps with accurate health assessments positions it well for expansion into broader wellness and preventative health markets, especially as remote health monitoring becomes increasingly mainstream. This creates opportunities to target telehealth providers and wellness platforms.

Tech-Driven Engagement The company's use of smartphone-based apps for personalized health monitoring (including the Fingernail Selfie feature) offers scalable, tech-savvy solutions for engaging diverse populations. Sales efforts can focus on healthcare organizations and telemedicine services looking to leverage innovative, non-invasive diagnostic capabilities.